Our unique and patented adjuvant technology enables intranasal vaccines that elicit antibodies in the blood as well as across mucosal surfaces. These mucosal antibodies serve as “Bouncers at the Door” to keep infections out. Our studies point to increased protection against some of the world’s most severe respiratory and sexually transmitted diseases.
BlueWillow’s intranasal vaccine technology has demonstrated safety and immunogenicity in Phase 1 clinical studies for seasonal influenza. Several other programs have advanced through successful challenge studies in primary animal models. Choose a pathogen and click for details on our research results and partnering information.